BioSig Technologies, Inc.

NASDAQ:BSGM

Tapping the Fast-Growing EP Market

Initially, we are targeting the $4.6 billion electrophysiology (EP) market, which is growing at more than 10% annually and expected to exceed $8.5 billion by 2024*.

  • Solid cash position with no debt
  • Recent Insider buying and strong insider ownership
  • Summer 2020 completed $17.5 million institutional financing at $8 a share

Find out how BioSig is innovating the market. Join us as we develop new ways to help patients and physicians.

We respect your privacy. We do not sell, rent, or loan any information to any third party. Any information you give us is held with the utmost care and security, and will be used only in ways to which you have consented.

This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

BioSig is

Harnessing Biomedical Signal Processing

At BioSig, we're working to develop and deliver the advanced signal processing solutions that will unlock the future of bioelectronic medicine, starting with the PURE EP™ System.

PURE EP™ : Our Novel Real-Time Signal Processing Platform

The PURE EP™ System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording, and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory.

Our Company at a Glance

The Transformative Potential of

Bioelectronic Medicine

Bioelectronic medicine is a rapidly growing field of healthcare that explores how targeted electrical signals can harness the body’s natural mechanisms to diagnose and treat a range of diseases.

The field represents not just a narrow category of medical devices, but an entire approach to detecting and treating disease – using electrical pulses and the body’s own mechanisms as an adjunct or alternative to drugs and medical procedures.

Our Strength is in the Numbers

With over $22 million cash:

  • Conducted over 950 patient cases in nine medical centers by June 2021
  • Achieved first commercial sales in Q4 2020 and Q1 2021
  • Scaling up organization through increasing salesforce and extending relationships with world- class healthcare institutions
  • Robust US-based supply chain
  • Additional product pipeline covering novel therapies for autonomic nervous system disease
  • Expected to triple the customer base in 2021

NASDAQ:BSGM

Get Investor Info Now

BioSig: A Company Worth Watching

Unique Collaboration with Mayo Clinic

Our 10-year strategic agreement:

  • Collaboration on technology development
  • Joint IP filings
  • Licensing opportunties
  • Mayo Clinic has invested capital in the development of the PURE EP™ System

And the first PURE EP™ System was installed at the Mayo Clinic in Florida in January 2020.

Our First FDA-Cleared Product: Pure EP™ System

Addressing Unmet Clinical Need of More Reliable ECG Signals

This revolutionary signal processing platform is designed to reveal the full range of cardiac signals, providing electrophysiologists with signal clarity during atheter ablation procedures and related studies.

The Pure EP™ System Reduces "Noise"

The Pure EP™ System refines signal clarity by reducing signal "noise", allowing clinicians to deliver therapy during procedures with a higher precision than ever before.

The Pure EP™ System Aims to Increase Safety

The Pure EP™ System allows surgeons to potentially work more accurately, decreasing the probability of a repeat procedure, leading to an increase in procedure safety and efficacy profile.

Don't just watch us grow.
Be a part of it.

This is just the beginning.

2021 will bring new milestones with global reach. Check out our investor info to learn more about the exciting projects ahead.

Send Me Investor Info